| 1. |
劉又寧. 間隔十年我國慢性阻塞性肺疾病的發病率真的升高了嗎. 中華結核和呼吸雜志, 2019, 42(2): 81-82.
|
| 2. |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
|
| 3. |
Bowerman KL, Rehman SF, Vaughan A, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun, 2020, 11(1): 5886.
|
| 4. |
Komaromy A, Reider B, Jarvas G, et al. Glycoprotein biomarkers and analysis in chronic obstructive pulmonary disease and lung cancer with special focus on serum immunoglobulin G. Clin Chim Acta, 2020, 506(7): 204-213.
|
| 5. |
Pavi? T, Dilber D, Kifer D, et al. N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease. J Transl Med, 2018, 16(1): 323.
|
| 6. |
Kim JH, Park S, Hwang YI, et al. Immunoglobulin G subclass deficiencies in adult patients with chronic airway diseases. J Korean Med Sci, 2016, 31(10): 1560-1565.
|
| 7. |
Leitao Filho FS, Ra SW, Mattman A, et al. Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res, 2018, 19(1): 30.
|
| 8. |
蔡柏薔. 慢性阻塞性肺疾病診斷、處理和預防全球策略(2017 GOLD報告)解讀. 國際呼吸雜志, 2017, 37(1): 6-17.
|
| 9. |
Qin J, Qin Y, Wu Y, et al. Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis, 2018, 10(8): 4923-4930.
|
| 10. |
Ladjemi MZ, Martin C, Lecocq M, et al. Increased IgA Expression in lung lymphoid follicles in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2019, 199(5): 592-602.
|
| 11. |
McCullagh BN, Comellas AP, Ballas ZK, et al. Antibody deficiency in patients with frequent exacerbations of chronic obstructive pulmonary disease (COPD). PLoS One, 2017, 12(2): e0172437.
|
| 12. |
Koo HK, Vasilescu DM, Booth S, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir Med, 2018, 6(8): 591-602.
|
| 13. |
許尤松, 鮑永霞, 魏益梅. 中性粒細胞/淋巴細胞比率在慢性阻塞性肺疾病中的臨床價值. 臨床肺科雜志, 2020, 25(12): 1914-1916,1925.
|
| 14. |
Sidletskaya K, Vitkina T, Denisenko Y. The role of Toll-like receptors 2 and 4 in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2020, 15(7): 1481-1493.
|
| 15. |
周寅川, 榮蓉, 黃祎丹, 等. 慢性阻塞性肺疾病急性加重期患者出院后 30 d 內再入院的影響因素分析及 Nomogram 模型構建. 實用心腦肺血管病雜志, 2020, 28(8): 57-63.
|
| 16. |
?ahin F, Ko?ar AF, Aslan AF, et al. Serum biomarkers in patients with stable and acute exacerbation of chronic obstructive pulmonary disease: a comparative study. J Med Biochem, 2019, 38(4): 503-511.
|
| 17. |
Collins PF, Stratton RJ, Kurukulaaratchy RJ, et al. Influence of deprivation on health care use, health care costs, and mortality in COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13(11): 1289-1296.
|
| 18. |
Tang J, Curull V, Ramis-Cabrer D, et al. Preoperative body weight and albumin predict survival in patients with resectable lung neoplasms: role of COPD. Arch Bronconeumol, 2021, 57(1): 51-60.
|
| 19. |
Eapen MS, Myers S, Walters EH, et al. Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox. Expert Rev Respir Med, 2017, 11(10): 827-839.
|
| 20. |
Leitao Filho FS, Mattman A, Schellenberg R, et al. Serum IgG levels and risk of COPD hospitalization: A Pooled Meta-analysis. Chest, 2020, 158(4): 1420-1430.
|
| 21. |
盧斯霞. 丙種球蛋白作為感染所致的慢性阻塞性肺疾病急性惡化期預后標志物的可行性. 臨床與病理雜志, 2018, 38(9): 1864-1870.
|